On 5 October 2022, the Geneva Network organized a panel about the possible future implications of expanding the scope of the TRIPS waiver, in particular in relation to innovation and availability of diagnostics, therapeutics, and vaccines for health crises. Innovation Council’s Executive Director Jennifer Brant took part in this panel to share information about how bio-manufacturing infrastructure can be extended, and what policy actions governments can take to accelerate the process. She expressed the view that the June 2022 TRIPS waiver should be tested, and that evidence should be tabled as to the need to expand the waiver’s scope to cover additional categories of COVID health products, before WTO Members take further action.
Click here to watch the virtual meeting.